Dorma

Title(s):

• Director of Drug Development, DormaTarg, Inc.
• Associate Professor, Department of Pharmaceutical Sciences, University of Oklahoma

Education:

• B.S., Pharmacy, Cum Laude with Honors and Distinction, The Ohio State University, Colombus, Ohio
• Ph.D., Pharmacology and Toxiocology, Dartmouth Medical School, Hanover, New Hampshire

Memberships:

• Society of Toxicology
• The Association for Research in Vision and Ophthalmology
• The American Association for the Advancement of Science
• American Diabetes Association

Research Summary:

Our expertise is in pharmacology and toxicology with a particular focus on cancer drug discovery and pre-clinical drug development. With respect to my role as Director of Drug Development at DormaTarg, our research is to first shepherd our pipeline of agents toward FDA approval. Among other things, this process involves proof of anti-tumor efficacy using multiple tumor-bearing and genetic rodent tumor models. If proven efficacious, lead compounds are then tested for toxicity, specifically to determine a No Observable Adverse Effect Level (NOAEL), in rodent models. Leads are then tested for pharmacokinetic parameters such as organ distribution, biotransformation, oral biovailability, elimination half-life and drug clearance. Finally, leads are subjected to Good Laboratory Practice (GLP) standards in preparation for an Investigational New Drug (IND) application. We are also working with medicinal chemists to identify and modify an active pharmacophore for dormant tumor killing with our role being to provide suitable drug screening bioassays and to screen for more active, less toxic compounds. Finally, we are using these bioassays to screen chemical libraries for new pharmacophore for killing.

Selected Publications:

Ihnat, M.A., Thorpe, J.E., Kamat, C.D., Szabo, C., Green, D.E., Warnke, L.A., Lacza, Z., Cselenyák, A., Ross, K., Shakir, S., Piconi, L. and Ceriello, A. Role of Extra-Mitochondrial Reactive Species in a "Memory" of Vascular Stress Signaling Diabetologia, Accepted 3.15.07

Ihnat, M. A., Thorpe, J. E., and Ceriello, A. (2007). Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med.

Kamat, C. D., Green, D. E., Warnke, L., Thorpe, J. E., Ceriello, A., and Ihnat, M. A. (2007). Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett 249, 209-19.

Kamat, C. D., Thorpe, J. E., Shenoy, S. S., Ceriello, A., Green, D. E., Warnke, L. A., and Ihnat, M. A. (2007). A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization. BMC Cardiovasc Disord 7, 4.

Kamat, C.D., Green, D.E., Curilla, S., Warnke, L., Hamilton, J.W., Sturup, S., Clark,C. and Ihnat, M.A. Role of HIF signaling on tumorigenesis in response to chronic low dose arsenic administration, Toxicol Sci. 86:248-257 (2005)

Contact Information:

The University of Oklahoma College of Pharmacy
P.O. Box 26901
Oklahoma City, Oklahoma 73126-0901

Phone: (405) 271-8001 ext. 47965
Fax: (405) 271-3548